RT Journal Article
T1 Cu-doped hollow bioactive glass nanoparticles for bone infec-tion treatment
A1 Jiménez Holguín, Javier
A1 Sánchez Salcedo, Sandra
A1 Cicuéndez Maroto, Mónica
A1 Vallet Regí, María Dulce Nombre
A1 Salinas Sánchez, Antonio J.
AB In search of new approaches to treat bone infection and prevent drug resistance development, a nanosystem based on hollow bioactive glass nanoparticles (HBGN) of composition 79.5SiO2–(18-x)CaO–2.5P2O5–xCuO (x = 0, 2.5 or 5 mol-% CuO) was developed. The objective of the study was to evaluate the capacity of the HBGN to be used as nanocarriers of the broad-spectrum anti-biotic danofloxacin and source of bactericidal Cu2+ ions. Core-shell nanoparticles with specific surface areas close to 800 m2/g and pore volumes around 1 cm3/g were obtained by using hexa-decyltrimethylammonium bromide (CTAB) and poly (styrene)-block-poly (acrylic acid) (PS-b-PAA) as structure-directing agents. Flow cytometry studies showed the cytocompatibility of the nanoparticles in MC3T3-E1 pre-osteoblastic cell cultures. Ion release studies confirmed the release of non-cytotoxic concentrations of Cu2+ ions within the therapeutic range. Moreover, it was shown that the inclusion of copper in the system resulted in a more gradual release of da-nofloxacin that was extended over one week. The bactericidal activity of the nanosystem was evaluated with E. coli and S. aureus strains. Nanoparticles with copper were not able to reduce bacterial viability by themselves and Cu-free HBGN failed to reduce bacterial growth, despite releasing higher antibiotic concentrations. However, HBGN enriched with copper and da-nofloxacin drastically reduced bacterial growth in sessile, planktonic and biofilm states, which was attributed to a synergistic effect between the action of Cu2+ ions and danofloxacin. There-fore, the nanosystem here investigated is a promising candidate as an alternative for the local treatment of bone infections.
PB MDPI
SN 1999-4923
YR 2022
FD 2022-04-12
LK https://hdl.handle.net/20.500.14352/72637
UL https://hdl.handle.net/20.500.14352/72637
LA eng
NO RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)RESEARCHER ID M-3316-2014 (Antonio Salinas Sánchez)ORCID 0000-0002-8408-3389 (Antonio Salinas Sánchez)
NO Unión Europea. Horizonte 2020
NO Instituto de Salud Carlos III (ISCIII)
DS Docta Complutense
RD 6 may 2024